Laboratory Corporation of America Holdings Announces the Availability of Affymetrix (Bedford, Massachusetts)-Based Whole Genome Microarrays

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) is pleased to announce the availability of an ultra high-density microarray, Affymetrix based technology (Whole-Genome Sampling Analysis). The offering continues the numerous recent advances in LabCorp’s clinical genetics laboratory diagnostics. In 2005, LabCorp first offered the comparative genomic hybridization (CGH) based microarray diagnostics which focused on mental retardation and developmental delay. This targeted testing underscored the need for higher density whole genome coverage. The Affymetrix-based technology provides analysis of DNA copy number changes – identifying deletions, gene amplifications and loss of heterozygosity (LOH).